Fresh off ALS drug with­draw­al, Amy­lyx touts in­ter­im rare dis­ease da­ta for the same ther­a­py

A week af­ter vol­un­tar­i­ly pulling its ALS drug off the mar­ket fol­low­ing a failed Phase 3 tri­al, Amy­lyx Phar­ma­ceu­ti­cals out­lined a new di­rec­tion for the drug by pre­sent­ing in­ter­im da­ta in an­oth­er dis­ease.

On Wednes­day, the com­pa­ny shared new da­ta for AMX0035, the same chem­i­cal com­pound as the now-de­funct ALS drug Re­lyvrio, in a rare ge­net­ic con­di­tion called Wol­fram syn­drome. It’s a dis­ease that usu­al­ly man­i­fests in child­hood, with pa­tients ex­pe­ri­enc­ing symp­toms typ­i­cal­ly seen in di­a­betes (high blood sug­ar, high urine pro­duc­tion) that may progress to blind­ness and deaf­ness.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER